Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.

GLP-1 class of weight loss and diabetes drugs are linked to previously unrecognized health risks and benefits, according to a ...